Detection of additional occult malignancy though profiling of ctDNA in late-stage cancer patients.
暂无分享,去创建一个
L. Lacroix | Y. Loriot | A. Hollebecque | E. Rouleau | C. Massard | C. Sarkozy | M. Aldea | S. Ponce | P. Lavaud | F. Blanc-Durand | D. Vasseur | L. Cerbone | A. Italiano | J. Soria | F. Mosele | M. Sakkal | C. Parisi | A. Bayle | L Verlingue
[1] K. Pantel,et al. Liquid Biopsy: From Discovery to Clinical Application. , 2021, Cancer discovery.
[2] R. Yamashita,et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies , 2020, Nature Medicine.
[3] T. Clark,et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin , 2020, PloS one.
[4] David R. Jones,et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.
[5] K. Young,et al. MYD88 L265P Mutation in Lymphoid Malignancies. , 2018, Cancer research.
[6] K. Stamatopoulos,et al. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing , 2015, Clinical Cancer Research.
[7] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[8] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.